Empagliflozin Promotes Natriuresis in Diabetic Patients with Cirrhotic Refractory Ascites: A Proof-of-Concept Study
Journal of Gastrointestinal and Liver Diseases · 2026
DOI: 10.15403/jgld-6897 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2026. Verfasst von Rongya Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Liver Disease Center, Baoding People's Hospital, Baoding, China. shirongya9809@163.com. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Natriuresis, Sodium-Glucose Transporter 2 Inhibitors. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims: Interventional studies directly targeting natriuresis in refractory cirrhotic ascites are scarce, and no prospective study has examined whether sodium-glucose transporter 2 (SGLT2) inhibitor-induced glucosuria is associated with changes in renal sodium handling. We conducted a randomized, open-label, proof-of-concept study to characterize the short-term natriuretic response to empagliflozin in patients with diabetes and refractory ascites Methods: Adults with type 2 diabetes, decompensated cirrhosis, and refractory ascites were randomized 1:1 to empagliflozin 10 mg once daily plus standard care or standard care alone for 10 days. The primary outcome was the between-group difference in mean change in fractional excretion of sodium (FENa, %) from baseline (Day 0) to the mean of post-baseline Days 1, 3, 7, and 10, estimated using a linear mixed-effects model. Key secondary outcomes included 24-hour urinary sodium excretion, 24-hour urine volume, and mean daily paracentesis volume.
Results
Twenty-one participants were randomized (empagliflozin n=10; control n=11). In the empagliflozin group, the between-group difference in mean change in FENa from baseline to the post-baseline mean (days 1, 3, 7, and 10) was +0.44 percentage points (95%CI: 0.05-0.83; p=0.029). Empagliflozin increased 24-hour urinary sodium excretion by +92.1 mmol/24 h (95%CI: 47.1-137.2) and 24-hour urine volume by + 822 mL/24 h (95%CI: 403-1240) versus control. Mean daily paracentesis volume was 0.6 ± 0.4 L/day with empagliflozin and 1.3 ± 0.6 L/day with control (mean difference -0.70 L/day, 95%CI: -1.17 to -0.23). No serious adverse events occurred.
Conclusions
In this open-label, proof-of-concept study, empagliflozin was associated with improved short-term natriuretic indices over 10 days in diabetic patients with decompensated cirrhosis and refractory ascites, without serious adverse events. Larger, blinded, longer-term trials are warranted to confirm these preliminary findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Liver Disease Center, Baoding People's Hospital, Baoding, China. shirongya9809@163.com.
- Liver Disease Center, Beijing You'an Hospital, Capital Medical University, Beijing, China. doctorhighland@163.com.
- Safe Transfusion Lab, Beijing Red Cross Blood Center, Beijing, China. gaoyunyi@live.cn.
- Teachers College, Columbia University, New York, United States. lz3059@tc.columbia.edu.
- Liver Disease Center, Baoding People's Hospital, Baoding, China. qinw13582211840@163.com.
- Liver Disease Center, Baoding People's Hospital, Baoding, China. Zhaofengyisheng@126.com.
Zitieren
APA
Shi, R., Gao, Y., Gao, Y., Zhou, L., Qin, W., Zhao, F., Jia, J., & Hu, Z. (2026). Empagliflozin Promotes Natriuresis in Diabetic Patients with Cirrhotic Refractory Ascites: A Proof-of-Concept Study. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-6897
Vancouver
Shi R, Gao Y, Gao Y, Zhou L, Qin W, Zhao F, et al. Empagliflozin Promotes Natriuresis in Diabetic Patients with Cirrhotic Refractory Ascites: A Proof-of-Concept Study. Journal of Gastrointestinal and Liver Diseases. 2026. doi:10.15403/jgld-6897
BibTeX
@article{Shi2026,
author = {Shi, Rongya and Gao, Yuan and Gao, Yunyi and Zhou, Longzhen and Qin, Wei and Zhao, Feng and Jia, Jianru and Hu, Zhongjie},
title = {Empagliflozin Promotes Natriuresis in Diabetic Patients with Cirrhotic Refractory Ascites: A Proof-of-Concept Study},
journal = {Journal of Gastrointestinal and Liver Diseases},
year = {2026},
doi = {10.15403/jgld-6897}
}
EUVIMED